Blake Aftab - Oct 12, 2022 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Role: Chief Scientific Officer
Signature: /s/ Nick Harvey, Attorney-in-Fact
Stock symbol: ACET
Transactions as of: Oct 12, 2022
Transactions value $: -$126,638
Form type: 4
Date filed: 10/14/2022, 04:08 PM
Previous filing: Aug 8, 2022
Next filing: Oct 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACET	Common Stock	Options Exercise	$25K	+3.39K	+6.85%	$7.38^*	52.8K	Oct 12, 2022	Direct	F1
transaction	ACET	Common Stock	Sale	-$25.3K	-1.65K	-3.12%	$15.40^*	51.2K	Oct 12, 2022	Direct	F1
transaction	ACET	Common Stock	Tax liability	-$126K	-7.93K	-15.5%	$15.92^*	43.2K	Oct 13, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACET	Stock Option (Right to Buy)	Options Exercise	$0	-3.39K	-5.65%	$0.00	56.6K	Oct 12, 2022	Common Stock	3.39K	$7.38	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
F3	A total of 60,000 shares subject to an employee stock option were granted to the Reporting Person on October 12, 2021. 25% of the shares subject to the stock option vested and became exercisable on October 12, 2022, with the remainder vesting in equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continued service with the Issuer.